ZenInvestorZR Posted - 2 days ago

$AKYA Waiting for bottom

Thestocktraderhubzee Posted - 4 days ago

WATCHLIST NOV 20 2024 $SYM DA Davidson Maintains Buy on Symbotic, Maintains $47 Price Target $ATNM Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target $IMTX B of A Securities Maintains Buy on Immatics, Lowers Price Target to $15 $FUTU Citigroup Downgrades Futu Hldgs to Neutral, Raises Price Target to $95 $AKYA Piper Sandler Reiterates Overweight on Akoya Biosciences, Lowers Price Target to $3

anachartanalyst Posted - 5 days ago

$AKYA https://anachart.com/wp-content/uploads/ana_temp/1732042920_soc-img.jpg

OpenOutcrier Posted - 1 week ago

$AKYA (-30.0% pre) Akoya Biosciences GAAP EPS of -$0.21 misses by $0.01, revenue of $18.8M misses by $6.62M - SA https://ooc.bz/l/48303

Reesifer Posted - 1 week ago

$AKYA added 2.44 before close

RocketThief Posted - 1 week ago

$AKYA horrible, can’t touch this

DonCorleone77 Posted - 1 week ago

$AKYA Akoya Biosciences lowers FY24 revenue view to $80M-$85M, consensus $98.19M Due to persistent macro challenges during the year, Akoya expects revenue for the full year 2024 to now be in the range of $80 million to $85 million versus a prior range of $96 million to $104 million. As part of our ongoing commitment to maximizing shareholder value, the company is also actively evaluating a range of strategic alternatives to identify the best path forward for sustainable growth, profitability and long-term success.

DonCorleone77 Posted - 1 week ago

$AKYA Akoya Biosciences reports Q3 EPS (21c), consensus (20c) Reports Q3 revenue $18.80M, consensus $25.42M."Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and enhanced our readiness to absorb the headwinds we are facing," said Brian McKelligon, CEO of Akoya Biosciences. "We remain confident that Akoya's technologies will continue to be the preferred platform in the spatial biology market from discovery to diagnostics, supporting a return to topline growth in 2025, and beyond, and achievement of our profitability goals."

Manipulation13F Posted - 1 month ago

$AKYA I lost on this bigtime smfh..

Manipulation13F Posted - 1 month ago

$AKYA Akoya Biosciences’ stock is rising following the announcement that its CyberFusion and PhenoImager HT Sparrow Protonic platforms will be used in the Manifest program for tissue analysis. This could mark a significant advancement in research and diagnostics. I'm watching for upcoming results and developments.🍻

Manipulation13F Posted - 1 month ago

$AKYA strong hold for me, my predictions that this may consolidate here then make a move. Patience is key for this 💪🍻

PLATINUM_TRADES Posted - 1 month ago

$AKYA nice day today... We gonna keep it this has more on this break with $3.61 major resistance next imo🥊🥊🥊🥊

Tokoyama Posted - 1 month ago

$VRAX @Tokoyama says would it not be interesting if volume suddenly came into these shares and the price started moving quickly to the $3.75 upward resistance? $SRRK $AKYA $GANX

themacromindset Posted - 1 month ago

Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy $AKYA

Himel92 Posted - 2 months ago

The Last month Performance for $AKYA Opening Price: $2.25 Closing Price: $2.40 Highest Price: $2.68 Lowest Price: $2.12 Percentage Change: 6.67% Data analyst: ACON

AnaChart Posted - 3 months ago

$AKYA https://anachart.com/wp-content/uploads/ana_temp/1723575757_soc-img.jpg

BioGem Posted - 3 months ago

$AKYA The Q2 report has several critical negatives that are deteriorating, I will keep on adding to my short above $2. See my post from the previous quarter. Their current financial situation with rapidly dropping cash and hefty debt is too fragile. They do not seem to have a way out except more debt, equity offering with large dilution at low prices, or BK ultimately.

Thestocktraderhubzee Posted - 3 months ago

$AKYA Morgan Stanley Downgrades Akoya Biosciences to Equal-Weight, Lowers Price Target to $3

VrtcIl Posted - 3 months ago

Do not FOMO in $AKYA now. Consider waiting for consolidations and aim for entry points with a tighter stop to manage risk effectively based on the technical chart setup. Price: 2.29 Float: 22.4M Short Float: 13.4 % 💰 Dollar Volume: 11.9K ℹ️ USA | Medical Instruments & Supplies

DonCorleone77 Posted - 3 months ago

$AKYA Akoya Biosciences reports Q2 EPS (27c), consensus (27c) Reports Q2 revenue $23.2M, consensus $23.55M."Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performance," said Brian McKelligon, CEO of Akoya Biosciences. "We believe that Akoya's platforms are poised to lead the spatial biology market from discovery to diagnostics, while we also position the company to achieve near-term operating cash flow breakeven as we align our cost structure with our strategic objectives."

Stock_Titan Posted - 3 months ago

$AKYA Akoya Biosciences Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/AKYA/akoya-biosciences-reports-second-quarter-2024-financial-40frl6ko4edp.html

NVDAMillionaire Posted - 07/31/24

$AKYA Akoya Biosciences, Inc. (NASDAQ:AKYA) – Spatial Biology Leader Navigating Temporary Headwinds, Poised for Sustained Growth http://beyondspx.com/2024/07/29/akoya-biosciences-inc-nasdaqakya-spatial-biology-leader-navigating-temporary-headwinds-poised-for-sustained-growth/

Stock_Titan Posted - 4 months ago

$AKYA Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences https://www.stocktitan.net/news/AKYA/akoya-biosciences-to-report-second-quarter-2024-financial-results-on-ygpj9lg63vay.html

NVDAMillionaire Posted - 4 months ago

$AKYA Akoya Biosciences, Inc. (AKYA): Navigating Challenges and Charting a Path to Recovery http://beyondspx.com/2024/06/30/akoya-biosciences-inc-akya-navigating-challenges-and-charting-a-path-to-recovery/

Will2ride1 Posted - 5 months ago

$AKYA up📈yes

Wonka112 Posted - 5 months ago

$AKYA

Will2ride1 Posted - 5 months ago

$AKYA crank it

Will2ride1 Posted - 5 months ago

$AKYA I like it...buy time

G101SPM Posted - 5 months ago

$AKYA $2.38 ask. BUY/NEW LONG POSITION carries SPM 82.15 tag to $6.00 in midterm. note: 259 bits increase in its SPM tag since prior reading.

Rodmon77 Posted - 5 months ago

$AKYA Longterm 👉📢🏃‍➡️🏃‍➡️